PL2658844T3 - Nowe pochodne pirymidyn, ich wytwarzanie i ich zastosowanie farmaceutyczne jako inhibitorów fosforylacji AKT(pkb) - Google Patents

Nowe pochodne pirymidyn, ich wytwarzanie i ich zastosowanie farmaceutyczne jako inhibitorów fosforylacji AKT(pkb)

Info

Publication number
PL2658844T3
PL2658844T3 PL11805849T PL11805849T PL2658844T3 PL 2658844 T3 PL2658844 T3 PL 2658844T3 PL 11805849 T PL11805849 T PL 11805849T PL 11805849 T PL11805849 T PL 11805849T PL 2658844 T3 PL2658844 T3 PL 2658844T3
Authority
PL
Poland
Prior art keywords
pkb
akt
preparation
pharmaceutical use
pyrimidine derivatives
Prior art date
Application number
PL11805849T
Other languages
English (en)
Inventor
Maurice Brollo
Jean-Christophe Carry
Victor Certal
Eric Didier
Gilles Doerflinger
Ahmad Youssef El
Bruno Filoche-Romme
Frank Halley
Karl Andreas Karlsson
Laurent Schio
Fabienne Thompson
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1061298A external-priority patent/FR2969609B1/fr
Priority claimed from FR1061303A external-priority patent/FR2969607B1/fr
Priority claimed from FR1061297A external-priority patent/FR2969608B1/fr
Priority claimed from FR1061300A external-priority patent/FR2969610B1/fr
Priority claimed from FR1061301A external-priority patent/FR2969614A1/fr
Application filed by Sanofi filed Critical Sanofi
Publication of PL2658844T3 publication Critical patent/PL2658844T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL11805849T 2010-12-28 2011-12-22 Nowe pochodne pirymidyn, ich wytwarzanie i ich zastosowanie farmaceutyczne jako inhibitorów fosforylacji AKT(pkb) PL2658844T3 (pl)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
FR1061298A FR2969609B1 (fr) 2010-12-28 2010-12-28 Nouveaux derives de 6-oxo-dihydro-pyrimidine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
FR1061303A FR2969607B1 (fr) 2010-12-28 2010-12-28 Nouveaux derives de thiopyrimidinones, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
FR1061297A FR2969608B1 (fr) 2010-12-28 2010-12-28 Nouveaux derives de (5-halo-6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
FR1061300A FR2969610B1 (fr) 2010-12-28 2010-12-28 Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-indolinamide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
FR1061301A FR2969614A1 (fr) 2010-12-28 2010-12-28 Nouveaux derives de pyrimidinones, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
FR1159317 2011-10-14
FR1159315 2011-10-14
FR1159313 2011-10-14
FR1159316 2011-10-14
EP11805849.4A EP2658844B1 (fr) 2010-12-28 2011-12-22 Nouveaux derives de pyrimidines, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)

Publications (1)

Publication Number Publication Date
PL2658844T3 true PL2658844T3 (pl) 2017-04-28

Family

ID=45464546

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11805849T PL2658844T3 (pl) 2010-12-28 2011-12-22 Nowe pochodne pirymidyn, ich wytwarzanie i ich zastosowanie farmaceutyczne jako inhibitorów fosforylacji AKT(pkb)

Country Status (12)

Country Link
US (1) US9133168B2 (pl)
EP (1) EP2658844B1 (pl)
CY (1) CY1118858T1 (pl)
DK (1) DK2658844T3 (pl)
ES (1) ES2612492T3 (pl)
HR (1) HRP20170119T1 (pl)
HU (1) HUE030393T2 (pl)
LT (1) LT2658844T (pl)
PL (1) PL2658844T3 (pl)
PT (1) PT2658844T (pl)
SI (1) SI2658844T1 (pl)
WO (1) WO2012089633A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103819422A (zh) * 2014-03-18 2014-05-28 南通佰华生物医药研究有限公司 一种制备手性n-取代-2-吗啉甲醇类化合物的方法
MA40059A (fr) 2014-06-13 2015-12-17 Gilead Sciences Inc Inhibiteurs de la phosphatidylinositol 3-kinase
US10221197B2 (en) 2014-06-13 2019-03-05 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
AU2015274637B2 (en) 2014-06-13 2018-04-19 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
AU2015274626C1 (en) 2014-06-13 2018-08-09 Gilead Sciences, Inc. Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors
AU2015274635B2 (en) 2014-06-13 2018-04-19 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2018057808A1 (en) 2016-09-23 2018-03-29 Gilead Sciences, Inc. Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CN106966951B (zh) * 2017-04-21 2020-01-31 常州佳德医药科技有限公司 4-氟-2-甲基吲哚及其制备方法和应用
EP4146205A4 (en) 2020-05-05 2024-05-29 Nuvalent, Inc. HETEROAROMATIC MACROCYCLIC ETHERS AS CHEMOTHERAPEUTIC AGENTS
IL297832A (en) 2020-05-05 2023-01-01 Nuvalent Inc Macrocyclic heteroaromatic chemotherapeutic agents
CN115707685A (zh) * 2021-08-20 2023-02-21 中国石油化工股份有限公司 一种制备胺-环氧卤丙烷聚合单体的方法及产物和系统
TW202320768A (zh) 2021-10-01 2023-06-01 美商努法倫特公司 雜芳族大環醚化合物之固體形式、醫藥組成物及製備

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4416884A (en) 1978-04-12 1983-11-22 Otsuka Pharmaceutical Co., Ltd. Piperazinylbenzoheterocyclic compounds
CN1891693A (zh) 2000-01-24 2007-01-10 基纳西亚股份有限公司 用于治疗的吗啉代基取代的化合物
GB0119865D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
US7598377B2 (en) 2002-08-16 2009-10-06 Astrazeneca Ab Inhibition of phosphoinositide 3-kinase β
RU2313524C2 (ru) 2003-05-09 2007-12-27 Ф.Хоффманн-Ля Рош Аг МИТИЛИНДОЛЫ И МЕТИЛПИРРОЛОПИРИДИНЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВНОСТЬЮ α-1-АДРЕНЕРГИЧЕСКИХ АГОНИСТОВ
US20070083053A1 (en) * 2003-06-27 2007-04-12 Nissan Chemical Industries, Ltd. Process for producing indole compound
WO2006019831A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
ITMI20060621A1 (it) 2006-03-31 2007-10-01 Dac Srl Nuova classe di inibitori delle istone deacetilasi
AR053358A1 (es) 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
US20090035394A1 (en) 2005-05-26 2009-02-05 Graeme Cameron Murray Smith Use of dna-pk inhibition to sensitise atm deficient cancers to dna-damaging cancer therapies
BRPI0616459A2 (pt) 2005-09-29 2011-06-21 Wyeth Corp compostos das fórmulas i, ii, e iii; processos para o tratamento ou para a prevenção de: um estado de saúde com melhora devido à recaptação de monoamina; pelo menos um sintoma vasomotor; pelo menos um distúrbio depressivo; pelo menos uma disfunção sexual; para a prevenção de dor; de distúrbio gastrointestinal ou genitourinário; de sìndrome de fadiga crÈnica; de sìndrome de fibromialgia; de esquizofrenia; e uso de um composto
TWI418556B (zh) * 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
WO2008064244A2 (en) 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
WO2008148074A2 (en) 2007-05-24 2008-12-04 Research Foundation Of State University Of New York Inhibitors of mtor and methods of treatment using same
CN101809002B (zh) 2007-07-09 2013-03-27 阿斯利康(瑞典)有限公司 用于与mtor激酶和/或pi3k相关的疾病中的吗啉代嘧啶衍生物
BRPI0814503A2 (pt) 2007-07-09 2017-05-16 Astrazeneca Ab composto, uso de um composto, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente, e para tratar uma doença, e, composição farmacêutica
US20100261723A1 (en) 2007-07-09 2010-10-14 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
AU2008273889B2 (en) 2007-07-09 2012-03-08 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
WO2009023233A1 (en) 2007-08-14 2009-02-19 Concert Pharmaceuticals, Inc. Substituted oxazolidinone derivatives
EP2062889A1 (de) 2007-11-22 2009-05-27 Boehringer Ingelheim Pharma GmbH & Co. KG Verbindungen
US20100311582A1 (en) 2008-01-25 2010-12-09 Syngenta Crop Protection, Inc. Chemical compounds
WO2010056631A1 (en) 2008-11-12 2010-05-20 Schering Corporation Inhibitors of fatty acid binding protein (fabp)
TWI469965B (zh) 2008-12-22 2015-01-21 Ono Pharmaceutical Co 乙炔基吲哚化合物
SG10201402867TA (en) 2009-07-02 2014-08-28 Sanofi Sa Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors

Also Published As

Publication number Publication date
EP2658844A1 (fr) 2013-11-06
US9133168B2 (en) 2015-09-15
WO2012089633A1 (fr) 2012-07-05
HUE030393T2 (en) 2017-05-29
CY1118858T1 (el) 2018-01-10
US20130274253A1 (en) 2013-10-17
HRP20170119T1 (hr) 2017-03-24
LT2658844T (lt) 2017-02-10
EP2658844B1 (fr) 2016-10-26
PT2658844T (pt) 2017-01-24
WO2012089633A9 (fr) 2012-08-23
SI2658844T1 (sl) 2017-02-28
DK2658844T3 (en) 2017-02-06
ES2612492T3 (es) 2017-05-17

Similar Documents

Publication Publication Date Title
SI2658844T1 (sl) Novi derivati pirimidina, njihova priprava in njihova farmacevtska uporaba kot inhibitorje AKT(PKB) fosforilacije
IL266510B (en) History of aminopyrimidines, their preparation and pharmaceutical preparations containing them
IL220863A (en) Oxazole derivatives of kinase inhibitors, medicinal preparations containing them and their uses
IL224288A (en) Derivatives of converted pyrazolamide, pharmaceutical preparations containing them and their use
ZA201206223B (en) Certain kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions, and methods of use thereof
IL221823A (en) Pipridine-4-Il-Aztidine Derivatives as Jack 1 Suppressors
PT2655375E (pt) Derivados de pirimidinona, sua preparação e sua utilização farmacêutica
PL2562172T3 (pl) Pochodne sfelaktonu, ich kompozycje farmaceutyczne, sposoby wytwarzania i zastosowania
AP2013006816A0 (en) Ptocess for preparing pan-CDK inhibitors of the formula (I), and intermediates in the preparation
IL222858A0 (en) Pharmaceutical formulations comprising 1-(beta-d-glucopyranosyl)-2-thienylmethylbenzene derivatives as inhibitors of sglt
IL225824A0 (en) History of quinoxaline, their preparation and pharmaceutical preparations containing them
SG10201402867TA (en) Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
IL227406A (en) Pyrimidine Gyrase and Topoisemarase Suppressors IV preparations containing them and their uses
IL226094A0 (en) The history of pyrazine, their preparation and pharmaceutical preparations containing them
IL232701A (en) Pirazine compounds that inhibit sick kinase, pharmaceutical preparations that contain them and their use in the preparation of drugs
ZA201306416B (en) Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
IL227404A0 (en) Pyrimidine history, their preparation and pharmaceutical preparations containing them
IL233415A0 (en) Imidazopyridine derivatives of tyrosine kinase inhibitors, preparations containing them and their uses
IL214408A0 (en) Derivatives of 6-(6-substituted-triazolopyidazine-sulfanyl) 5-fluoro-benzothiazoles and 5-fluoro-benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors
IL225823A0 (en) History of quinazoline, their preparation and pharmaceutical preparations containing them
IL225378A0 (en) History of phenylquinazoline, their preparation and pharmaceutical preparations containing them
HK1192754A (en) Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
HK1177101A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
HK1163691A (en) Derivatives of 6-(6-substituted-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles and 5-fluoro-benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors
HK1184073A (en) Oral formulation of kinase inhibitors